Home » Pre-Menstrual Syndrome Treatment Market

Pre-Menstrual Syndrome Treatment Market By Drug (Analgesics (Pain Killers), Oral Contraceptive Pills (OCPs), Gonadotropin-Releasing Hormone (GnRH), Antidepressants, Ovarian Suppressors, Diuretics, Benzodiazepines) – Growth, Future Prospects And Competitive Analysis, 2016 – 2024

Price: $4999

Published: | Report ID: 11248 | Report Format : PDF

Market Insights

Premenstrual syndrome (PMS) is a medical condition in women that occurs during childbearing age. It is estimated that more than one in three women suffers from PMS, and one in every twenty women demonstrates life-disturbing symptoms. Premenstrual dysphoric disorder (PMDD) is a further severe form of PMS and demonstrates more severe symptoms of PMS, often interfering with social activities, work, and emotional balance. PMDD occurs in 3% to 5% of menstruating women. Though the exact cause of PMS is unknown, it is reported that fluctuating levels of hormones (estrogen and progesterone) are related to PMS symptoms. The treatment regimen for PMS is temporary, i.e., administered only for symptom management before the onset of the menstrual cycle. Education, nutrition, exercise, and medication together form the complete layout of the PMS treatment module.

The report titled “Premenstrual Syndrome Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2016–2024” offers strategic insights into the overall premenstrual syndrome treatment market, along with the market size and estimates for the duration of 2014–2024. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies. The drug types studied for analyzing the overall global premenstrual syndrome treatment market are majorly segmented into analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics, and benzodiazepines.

Geographically, the global premenstrual syndrome treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2014–2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global premenstrual syndrome treatment market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive landscape of the global premenstrual syndrome treatment market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global premenstrual syndrome treatment market. In-depth competitive environment analysis and historical (2014) market size data are also provided in the report.

Based on the type of drug, the global premenstrual syndrome treatment market is segmented as follows:

  • Analgesics (pain killers)
  • Oral contraceptive pills (OCPs)
  • Gonadotropin-releasing hormone (GnRH)
  • Antidepressants
  • Ovarian Suppressors
  • Diuretics
  • Benzodiazepines

NSAIDs and paracetamol are common pain relievers used to treat PMS. This market is dominated by over-the-counter drugs, which are inexpensive and widely available. For depression and anxiety, particularly in patients with PMDD, drugs such as SSRIs (commonly fluoxetine and sertraline) are commonly prescribed. GnRH, i.e., synthetic hormones, are prescribed to initiate temporary menopause in patients with severe PMS. It is observed that the demand for hormone-based PMS treatments is on a perpetual rise and will continue through the forecast period.

For the purpose of this study, the global premenstrual syndrome treatment market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

At present, North America and Europe dominate the premenstrual syndrome treatment market due to an increase in the prevalence of the syndrome and higher awareness of the syndrome and prevailing treatment options. The Asia Pacific, the Middle East, and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. A large pool of females of childbearing age, a growing literacy rate, and a working population significantly contribute to growing opportunities in the region. A growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market’s growth.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Pre-menstrual Syndrome Treatment Market Portraiture
2.2 Global Pre-menstrual Syndrome Treatment Market Share, by Drug type, 2015 (US$ Mn)
2.3 Global Pre-menstrual Syndrome Treatment Market, by Geography, 2015 (Value %)

Chapter 3 Global Pre-menstrual Syndrome Treatment Market Analysis
3.1 Global Pre-menstrual Syndrome Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing Awareness about PMS has Attracted the Demand for PMS Management Drugs
3.2.2 Challenges
3.2.2.1 Lack of Social Appreciation and Attachment of Stigma
3.2.3 Opportunities
3.2.3.1 Proliferation of Basic Healthcare Campaigns and Initiatives
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Pre-menstrual Syndrome Treatment Market

Chapter 4 Global Pre-menstrual Syndrome Treatment Market Analysis, by Drugs Type, 2014-2024 (US$ Mn)
4.1 Introduction
4.2 Analgesics (pain killers)
4.3 Oral Contraceptive Pills (OCPs)
4.4 Gonadotropin-releasing Hormone (GnRH)
4.5 Antidepressants
4.6 Ovarian Suppressors
4.7 Diuretics
4.8 Benzodiazepines

Chapter 5 Global Pre-menstrual Syndrome Treatment Market, By Geography, 2014-2024 (US$ Mn)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 6 Company Profiles
6.1 Alva-Amco Pharmacal Cos., Inc.
6.2 Bayer, Inc.
6.3 Chattem, Inc. (Sanofi)
6.4 DEKK-TEC, Inc.
6.5 G. R. Lane Health Products Ltd
6.6 McNeil Consumer Healthcare
6.7 MetP Pharma AG
6.8 Pherin Pharmaceuticals, Inc.
6.9 Umecrine Mood AB
6.10 Umecrine Mood AB
6.11 Novartis AG
6.12 GlaxoSmithKline Plc

List of Figures

FIG. 1 Global Pre-menstrual Syndrome Treatment Market: Research Methodology
FIG. 2 Global Pre-menstrual Syndrome Treatment Market Share, by Drug type, 2015 (US$ Mn)
FIG. 3 Global Pre-menstrual Syndrome Treatment Market, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition: Global Pre-menstrual Syndrome Treatment Market, by Geography
FIG. 5 Competitive Analysis: Key Players in Global Pre-menstrual Syndrome Treatment Market
FIG. 6 Pre-menstrual Syndrome Treatment Analgesics (pain killers) Market, 2014 – 2024 (US$ Mn)
FIG. 7 Pre-menstrual Syndrome Treatment Oral Contraceptive Pills (OCPs) Market, 2014 – 2024 (US$ Mn)
FIG. 8 Pre-menstrual Syndrome Treatment Gonadotropin-releasing Hormone (GnRH) Market, 2014 – 2024 (US$ Mn)
FIG. 9 Pre-menstrual Syndrome Treatment Antidepressants Market, 2014 – 2024 (US$ Mn)
FIG. 10 Pre-menstrual Syndrome Treatment Ovarian Suppressors Market, 2014 – 2024 (US$ Mn)
FIG. 11 Pre-menstrual Syndrome Treatment Diuretics Market, 2014 – 2024 (US$ Mn)
FIG. 12 Pre-menstrual Syndrome Treatment Benzodiazepines Market, 2014 – 2024 (US$ Mn)

List of Tables

TABLE 1 Global Pre-menstrual Syndrome Treatment Market, 2014-2024 (US$ Mn)
TABLE 2 Global Pre-menstrual Syndrome Treatment Market, by Geography, 2014 – 2024 (US$ Mn)
TABLE 3 North America Pre-menstrual Syndrome Treatment Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 4 Europe Pre-menstrual Syndrome Treatment Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 5 Asia-Pacific Pre-menstrual Syndrome Treatment Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 6 Latin America Pre-menstrual Syndrome Treatment Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 7 Middle East and Africa Pre-menstrual Syndrome Treatment Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 8 Alva-Amco Pharmacal Cos., Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 9 Bayer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 10 Chattem, Inc. (Sanofi): Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 DEKK-TEC, Inc.: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 12 G. R. Lane Health Products Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 McNeil Consumer Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 MetP Pharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Pherin Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Umecrine Mood AB: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Umecrine Mood AB: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Novartis AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Pre-Menstrual Syndrome Treatment Market?

The market for Pre-Menstrual Syndrome Treatment Market is expected to reach US$ 4,985.7 Mn in 2024.

What is the Pre-Menstrual Syndrome Treatment Market CAGR?

The Pre-Menstrual Syndrome Treatment Market is expected to see significant CAGR growth over the coming years, at 2.0%

What is the Forecast period considered for Pre-Menstrual Syndrome Treatment Market?

The report is forecasted to 2016-2024.

What is the base year considered for Pre-Menstrual Syndrome Treatment Market?

The base year of this report is 2015.

Who are the major players in this Market?

Alva-Amco Pharmacal Cos., Inc., Bayer, Inc.,Chattem, Inc. (Sanofi),DEKK-TEC, Inc.,G. R. Lane Health Products Ltd are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN